Continuing versus stopping daily aspirin before colonoscopy with possible polyp removal
Official title: Aspirin Continuation or Interruption in Patients at Moderate Risk for Cardiovascular Events Undergoing Colonoscopy and/or Polypectomy; a Placebo-controlled Trial
Run by Chinese University of Hong Kong · NCT07052799 · Data updated 2026-11-12
This trial tests whether people taking daily low‑dose aspirin to prevent heart problems should keep taking aspirin or stop it before an elective colonoscopy with possible polyp removal to balance heart and bleeding risks.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 2514 (estimated) |
| Sponsor | Chinese University of Hong Kong Academic / other |
| Locations | 1 site (Hong Kong) |
| Status | Recruiting |
| Started | February 10, 2026 |
| Main results expected | December 31, 2030 |
| Study ends | December 31, 2031 |
| Registry record updated | March 18, 2026 |
| Trial ID | NCT07052799 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are people taking daily aspirin (≥80 mg) for secondary prevention of cardiovascular disease who need an elective colonoscopy and possible polypectomy and who do not have recent stents, recent cardiac events, use of anticoagulants or other antiplatelet drugs, bleeding disorders, or terminal illness.
✕Probably not a fit
Patients with a coronary stent within 6 months, a cardiovascular event within 3 months, concurrent anticoagulant or P2Y12 inhibitor use, active bleeding disorders, or terminal illnesses are excluded and would not benefit from participating.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a randomized, phase 3 trial comparing continuation of daily low‑dose aspirin (80 mg) versus interruption (placebo) in patients who take aspirin for secondary cardiovascular prevention and are undergoing elective colonoscopy with potential polypectomy. Participants are randomly assigned to continue aspirin or receive placebo around the time of the procedure, and outcomes include post‑polypectomy bleeding and cardiovascular events. The trial focuses on short‑term periendoscopic safety and clinically important bleeding and thrombotic endpoints. Results aim to provide randomized evidence to inform guideline recommendations about peri‑colonoscopy aspirin management.
Why it matters
Potential benefit: If successful, the trial could identify a safer approach that reduces heart complications from stopping aspirin without causing an unacceptable increase in bleeding after polypectomy.
How similar studies have gone: Most existing evidence comes from large retrospective cohort series suggesting low bleeding rates with aspirin continuation but there has been no prior randomized trial directly comparing continuation versus interruption in this setting.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * patients receiving aspirin (80mg daily or more) for secondary prevention against cardiovascular diseases who require elective colonoscopy for colorectal cancer screening. Exclusion Criteria: * patients who received a coronary stent of any type within 6 months * patients who had a cardiovascular event within 3 months * patients who had concurrent use of anticoagulants (warfarin or NOAC) or other antiplatelet drugs (P2Y12 receptor antagonists) * patient with bleeding diathesis e.g., hemophilia, von Willebrand's disease or coagulopathy from liver cirrhosis * patient with terminal malignancies or medical illnesses. * patient who is unable or refuse to give consents
Where it's running
-
Prince of Wales Hospital
Hong Kong, Hong Kong Recruiting
Study contacts
- Principal investigator: James Yun Wong Lau, MD — Chinese University of Hong Kong
- Study coordinator: James Yun Wong Lau, MD
- Email: laujyw@surgery.cuhk.edu.hk
- Phone: +85235051445
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Risk of malignant arrhythmias after acute coronary syndrome
This study tracks how often dangerous heart rhythms occur in adults admitted for ACS and looks for patterns that might predict them.
-
Smartphone AI help for prehospital ECG readings
This study tests whether using a smartphone AI (GPT-4o) to help prehospital providers read 12-lead ECGs improves accuracy in diagnosing acute coronary syndromes and related conditions.
-
Optimal timing of staged complete revascularization in STEMI with multivessel disease
This trial tests whether performing staged complete revascularization during the hospital stay or after discharge is best for STEMI patients with multivessel disease.
-
BEAT-SHOCK: Baseline Registry for Acute Cardiogenic Shock at Basel
This registry collects and shares data on adults with cardiogenic shock admitted to University Hospital Basel to help understand how these patients are treated and how they fare.
-
Low-dose IL-2 after heart attack to study tissue-resident regulatory T cells
Researchers are testing whether low-dose interleukin-2 given after a myocardial infarction can boost tissue-resident regulatory T cells to support heart repair.
-
Abbreviated antithrombotic therapy after PCI in AF and MI
This trial tests whether DOAC-only therapy works as well as DOAC plus clopidogrel after PCI in people with atrial fibrillation and a recent heart attack.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.